Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Mesothelioma, Malignant 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT00305084 2019-10-04

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

AGC Biologics S.p.A.

Phase 1 Completed
15 enrolled 20 charts
Tumor-Agnostic

Neoplasms

NCT00483509 2019-10-04

NGR007

AGC Biologics S.p.A.

Phase 2 Completed
28 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

NCT01098266 2019-09-17

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

AGC Biologics S.p.A.

Phase 3 Completed
400 enrolled 16 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡